Rob Capon

Prof. Rob Capon

The University of Queensland, Institute for Molecular Bioscience
+1
orcid

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2023 in The Journal of Antibiotics
Verified
Journal Article
Open access
PDF file
Mark ButlerMark Butler
Mark Butler
IHIan R. Henderson
Ian R. Henderson
Rob CaponRob Capon
Rob Capon
Mark BlaskovichMark Blaskovich
Mark Blaskovich
The need for new antibacterial drugs to treat the increasing global prevalence of drug-resistant bacterial infections has clearly attracted global attention, with a range of existing and upcoming funding, policy, and legislative initiatives designed to revive antibacterial R&D. It is essential to assess whether these programs are having any real-world impact and this review continues our systematic analyses that began in 2011. Direct-acting antibacterials (47), non-traditional small molecule antibacterials (5), and β-lactam/β-lactamase inhibitor combinations (10) under clinical development as of December 2022 are described, as are the three antibacterial drugs launched since 2020. Encouragingly, the increased number of early-stage clinical candidates observed in the 2019 review increased in 2022, although the number of first-time drug approvals from 2020 to 2022 was disappointingly low. It will be critical to monitor how many Phase-I and -II candidates move into Phase-III and beyond in the next few years. There was also an enhanced presence of novel antibacterial pharmacophores in early-stage trials, and at least 18 of the 26 phase-I candidates were targeted to treat Gram-negative bacteria infections. Despite the promising early-stage antibacterial pipeline, it is essential to maintain funding for antibacterial R&D and to ensure that plans to address late-stage pipeline issues succeed.

10 February 2016 in Journal of Natural Products
Verified
Journal Article
Open access
SVSoumini Vijayasarathy
Soumini Vijayasarathy
PPPritesh Prasad
Pritesh Prasad
LFLeith J. Fremlin
Leith J. Fremlin
RRRanjala Ratnayake
Ranjala Ratnayake
ASAngela A Salim
Angela A Salim
Rob CaponRob Capon
Rob Capon
We validate the improved resolution and sensitivity of the C3 Marfey’s method, including an ability to resolve all Ile isomers, against an array of amino acids commonly encountered in natural products and by comparison to an existing Marfey’s method. We also describe an innovative 2D C3 Marfey’s method as an analytical approach for determining the regiochemistry of enantiomeric amino acid residues in natural products. The C3 and 2D C3 Marfey’s methods represent valuable tools for probing and defining the stereocomplexity of hydrolytically accessible amino acid residues in natural products.

25 October 2007 in Journal of Natural Products
Verified
Journal Article
Closed access
Rob CaponRob Capon
Rob Capon
MSMichael Stewart
Michael Stewart
RRRanjala Ratnayake
Ranjala Ratnayake
ELErnest Lacey
Ernest Lacey
JGJennifer H. Gill
Jennifer H. Gill

10 September 2012 in Organic Letters
Verified
Journal Article
Closed access
FSFuhang Song
Fuhang Song
XLXinru Liu
Xinru Liu
HGHui Guo
Hui Guo
BRBiao Ren
Biao Ren
CCCaixia Chen
Caixia Chen
Rob CaponRob Capon
Rob Capon

6 December 2012 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
QWQian Wang
Qian Wang
FSFuhang Song
Fuhang Song
XXXue Xiao
Xue Xiao
PHPei Huang
Pei Huang
LLLi Li
Li Li
LZLixin Zhang
Lixin Zhang
From the deep: The title actinomycete yielded three new abyssomicins J–L. The dimeric thioether J (see scheme) represents a unique example of a masked Michael acceptor with anti‐TB properties. Mechanistic insights into the biosynthesis, biomimetic synthesis, stability, and biological mechanism of action of abyssomicins aid our understanding of, and prospects for the development of Michael‐acceptor‐based drugs.

31 January 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
Mariusz SkwarczynskiMariusz Skwarczynski
Mariusz Skwarczynski
GZGuangzu Zhao
Guangzu Zhao
JBJennifer Boer
Jennifer Boer
VOVictoria Ozberk
Victoria Ozberk
AAArmira Azuar
Armira Azuar
Istvan TothIstvan Toth
Istvan Toth
A new vaccine immunostimulatory (adjuvant) system was developed based on fully defined polymers built from native amino acids.